Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies

Abstract Background Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies. However, the use of allogeneic T cells in CAR therapy poses a challenge due to the risk of graft-v...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yingling Zu, Quan Ren, Jishuai Zhang, Hongchang Su, Qiumei Lu, Yongping Song, Jian Zhou
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-10-01
coleção:	Experimental Hematology & Oncology
Assuntos:	Chimeric antigen receptor Nature killer cells CD5 T-cell malignancies
Acesso em linha:	https://doi.org/10.1186/s40164-024-00577-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!